PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials

Category Systematic review
JournalBIOMEDICAL RESEARCH AND THERAPY
Year 2023
This article has no abstract
Epistemonikos ID: ba4670fa912b729eab3aac01e27132ba40486ab7
First added on: Feb 17, 2025